www.copdjournal.com in Malmö, Sweden (1997). 6 Th is registry is web-based and includes, on November 2014, 18 countries and 5147 patients.
In 1999, Belgium joined AIR, which resulted in 2001, in a fi rst Belgian working group settled by the Belgian Th oracic Society. Th e objectives of the group were to disseminate information concerning AATD, to promote the recommended screening for AATD, to promote preventive measures and to promote registration of cases.
Each Belgian chest physician can receive a web access to the Belgian AAT registry after inscription by the Belgian Th oracic Society. After introduction of new patients, the registry administrator will validate the case if the data have been correctly entered. Th e fi rst Belgian patients were included in the AIR registry in 2003.
In December 2005, R. Stockley, chairman of AIR, was invited for participating to the Annual Meeting of the Belgian Th oracic Society. His presentation of the topic "COPD interventions: lessons from AATD" gave an important impulse to the activities of the Belgian Working Party. In September 2005, 18 patients were included in the Belgian registry and, in March 2006, 27 Belgian patients were included (50% new cases in 6 months). Nevertheless, only 0.93% of the 2,627 expected severe defi cient patients were registered.
Currently, 55 patients are included in the Belgian registry, 36 males and 19 females. Of them 46 phenotyped patients are also included in AIR. Th ere were only 9 non-smokers but 36 had stopped smoking. Nearly all patients tested for AAT were suff ering from lung disease. Six patients were diagnosed in a context of family screening. In no patient fi rst analysis was done for a hepatic disease but 2 had a history of neonatal hepatitis. Eighteen patients were lung transplanted, 1 liver transplanted. Sixteen patients had, on registration, benefi ted from augmentation therapy, and 5 from long-term oxygenotherapy. Between 1.6 and 2.1% of the estimated cases are currently registered.
Belgian participation to the pediatric Alpha1-International Registry (AIR)
Th irty-one severe Pi*ZZ AAT defi cient patients are followed in Brussels in "Cliniques Universitaires St Luc" by the Gastroenterology and Hepatology Pediatric Service. 7 Since 2014, most of these patients were included in the Alpha one International Registry (AIR).
Position paper of the Belgian Thoracic Society
In December 2009, during the annual meeting of the Belgian Th oracic Society, Belgian Guidelines for Diagnosis and Management of Patients with alpha1-Antitrypsin Defi ciency were presented and published on the offi cial site of the Society. 8 Th e recommendations were summarized as follows:
1. Screening for alpha1-Antitrypsin (AAT) defi ciency should be systematically performed on patients with emphysema (regardless of smoking history), COPD, bronchiectasis without evident aetiology, asthma with persistent obstruction despite treatment, liver disease without evident aetiology, off spring or pa rents of an individual with an AAT defi ciency (fi rst degree collaterals), absence of an AAT peak on electrophoresis, and unexplained panniculitis or anti-proteinase3 vasculitis. 2. Th e result of a normal or abnormal AAT serum level should be saved in the appropriate section of the patient's record to avoid needless retesting. 3. Looking at the AAT serum level, we can decide that the classical threshold above which a patient will not be sick or even carrier of a Z allele is above 150 mg/dL. Looking at the patients from the Spanish and Italian registries, Costa et al 9 and Gorrini et al 10 tried to clarify the level of normality above which they did not have to request complementary blood analyses for detecting defi cient individuals or carriers. Th ey proposed similar threshold values, 114 and 113 mg/dL, respectively. Th ey only recommended phenotyping or genotyping patients whose serum levels were under these thresholds. We can adopt this strategy which permits, at a lower cost, to detect effi ciently patients suff ering of severe AAT defi ciency and carriers. 4. Patients with an AAT serum level <114 mg/dL, should undergo a pheno-and/or genotyping by sending appropriate samples to one of the reference labs in Belgium or by sampling three large blood droplets (0,5 mL of blood in total) on a special card (dried blot spots). 5. Cards can be obtained at no cost from the secretariat of the Belgian Society of Pneumology. 6. Cards to be sent by post to the Belgian Th oracic Society secretariat, after fi lling in clinical and administrative data. Th ey will be forwarded to one European reference laboratory (Marburg, Germany) for pheno-and genotyping. 7. Th e Marburg Laboratory will communicate the result to the physician. 8. In return, physicians are requested to register their patients with severe AAT defi ciency (serum level < 50 mg/dL, Pi*Null-Null, Pi*Z-Null, Pi* ZZ, Pi*SZ, Pi*S-Null), once the phenotype is known, via the web site ( http://www.air-registry.org/be/ ). 9. Patients with severe AAT defi ciency should be informed about the natural history of the disease and the importance of stopping smoking. Management of severe AAT defi ciency should focus on COPD treatment according to guidelines, aggressive treatment of pulmonary infections, vaccinations against infl uenza, hepatitis A and hepatitis B, annual followup of pulmonary function and imaging, liver tests, α-fetoprotein, liver echography. Augmentation therapy should be considered in non-or ex-smokers with AAT serum level under 50 mg/dL (11 μmol/L) and with moderate to severe obstruction (FEV 1 between 30-65% predicted) or with a rapid decline in FEV 1 . 10. Genetic testing should be performed in all fi rst degree relatives of a homozygous or heterozygous AAT defi cient patient (Z or Null allele carrier). Genetic counselling could be provided.
AAT Augmentation Therapy in Belgium
Th e substitution therapy with purifi ed AAT obtained from human serum has been approved by the US Food and Drug Administration (FDA) in 1987. It remains the only applicable specifi c therapy for the disease but controversy remains concerning effi cacy. Augmentation infusions increase circulating trough levels of AAT to levels approximating those seen in heterozygous. A protective level of active AAT is restored in the epithelial lining fl uid.
Augmentation therapy was available and almost completely reimbursed in Belgium until mid-2010 and 26 patients were treated. Th ereafter the National Institute for Disease and Invalidity Insurance decided to continue to reimburse the treatment only for those patients who were already receiving it. No additional patient could be reimbursed for AAT substitution. 11 Th erefore, since 2010, augmentation therapy is no longer reimbursed in Belgium for new patients.
Th e Belgian Th oracic Society's workgroup has been recently requested to express an opinion on the selection of patients who could benefi t from the augmentation therapy. A discussion is ongoing for defi ning eventual new conditions of reimbursement by the social security.
To eff ectively limit the costs of treatment, recent studies aimed at targeting better the patients particularly at risk and the most susceptible to benefi t from AAT substitution. Stockley et al. 12 suggested the importance of a personalized approach considering the severity of the lung disease, the rate of decline in lung function, age and frequency of exacerbations.
At the moment, we propose to consider substitution therapy in non-smokers or ex-smokers suff ering from a severe AAT defi ciency with a plasma level <50 mg/ mL, with a FEV 1 in the range of 30-60% predicted and a FEV 1 decline of at least 0.5% predicted per year.
For estimating the decline of functional parameters, a longitudinal analysis for at least 2-3 years is required. Th e measures of lung physiology must be done at least 6 weeks after any exacerbation and when smoking has ceased.
Patients with an FEV 1 in range of 60-80% predicted would be followed up unless they demonstrate a particularly rapid decline of FEV 1 in excess of 1.0% predicted per year.
No recommendation has been published concerning the interpretation of lack of effi cacy and treatment withdrawal criteria. It is evident that a longitudinal follow-up of at least 3 years would be necessary while on therapy to determine the subsequent FEV 1 decline. Continued decline at the pretreatment level or an increase in the rate of decline would require reassessment of augmentation strategy.
We analyzed in 2012 the patients actually benefi ting from augmentation therapy. We have collected the functional data and the follow-up values by questioning the treating chest physicians individually. We included 26 substituted patients and we were able to obtain the initial parameters of 24 of them.
Looking at the FEV 1 measured in 24 patients before initiating augmentation therapy (see Figure 1 ), 19 were www.copdjournal.com already in the limits suggested by the studies concerning effi cacy of substitution therapy and the ATS/ERS re commendations.
Lung and liver transplantation in Belgium
In 2010, Van Raemdonck and Verleden 13 discussed the indications and the results of lung transplantation for respiratory failure. Belgium is amongst the world leading countries in terms of lung donors and lung transplants per inhabitants. To date, the Belgian Lung Transplantation Registry accounts 821 transplants. Th irty-two patients are alphas (3.9%).
Th e "Cliniques Universitaires St Luc/Service de Gastroentérologie et Hépatologie pédiatrique" is a tertiary referral pediatric liver transplantation (LT) center under the supervision of Pr Etienne Sokal. In their center, they follow a cohort of 37 PiZZ AAT defi ciency patients. 7 In the cohort (from 1974 to 2014), male predominance was observed (24 males and 13 females). At the time of AATD diagnosis, 23 of 37 (62%) PiZZ patients had neonatal cholestasis and/or cirrhosis. Of course, the AATD phenotype distribution is biased as they are a referral LT center. Neonatal cholestasis was the initial presentation in 18 of 23 (11 males and 7 females) while cirrhosis was the initial presentation in 5 males. Th irteen (56%) of these 23 patients developed end-stage liver disease requiring LT, 11 of these 13 (85%) were males, accounting for 46% of all male patients and 2 were PiZZ females (15% of all female patients). Of 24 who did not require LT, 10 (42%) had presented with neonatal cholestasis (5 males and 5 females) and 14 had no history of severe liver disease and diagnosis was an incidental fi nding. Th ese results suggest a more severe evolution of liver disease in male children. All these patients did not have pulmonary symptoms at last follow-up.
Belgian patients group
Th e number of alpha patients in Belgium remained for a long time too small to permit the creation of a structure allowing an easy communication between Alphas. Having three national languages (French, Flemish and German) also does not help for simplifying a kind of exchange platform.
In 2012, when it was known that augmentation therapy would not be further reimbursed by the Public Health System for newly diagnosed Alphas, several Belgian patients met for trying to fi nd solutions. As in other countries where alpha patients' organizations are established, they decided to found a group and named it Alpha-1 Belgium. Th e association remained with no legal base or structure or subsides, but in contact with patients and medical doctors. Th e most important goals were to create awareness about the disease and to contact the Public Health Structures.
In 2013, the group was represented at the 4 th international Alpha-1 congress for patients hold in Barcelona and met other patient organizations but also attended the scientifi c program and conferences.
Another event in summer 2013 was the meeting with two members of the European Parliament to create awareness about the Belgian lack of reimbursement. Th e Belgian Minister of Public Health was contacted a month later.
In autumn 2013 the necessity for a stand-alone, legal and registered structure led the patient group to create a new not-for-profi t association called Alpha- Th ere are contacts with patient organizations in other countries (Germany, France, Denmark).
Finally, in June 2014, the Belgian association assisted to create another new structure called Alpha-1 Global, a group of 7 volunteers who are patient representatives of Alpha patient groups. Th e mission of Alpha-1 Global is to create a collaborative network of Alpha-1 organizations and patients to increase awareness, detection and access to care for Alphas around the world. Th e fi rst tool is to create an Internet platform for patients, medical and care professionals and researchers to communicate about the disease.
Conclusions
Th e Belgian activities concerning AAT defi ciency are growing. Th e screening and registration remain insuffi cient as it is also the case in nearly all other countries.
Nevertheless we can say that since 1999 and our participation in AIR we have put Belgium on the map. We will continue to boost the integrated activities of all the stakeholders involved in AAT defi ciency, with the ultimate goal to appropriately screen advice and eventually treat all AAT patients suff ering from this disabling disease.
Also, feedback from patients and communication with patients' organizations stimulate awareness and knowledge of this rare disease. 
